A conjugate comprising: (a) a monoclonal antibody or an antigen binding fragment thereof, wherein the monoclonal antibody or antigen binding fragment thereof comprises a heavy chain complementarity determining region 1 (HCDR1), a HCDR2, a HCDR3, a light chain complementarity determining region 1 (LCDR1), a LCDR2, and a LCDR3, having the polypeptide sequences of SEQ ID NO: 141, 142, 143, 144, 145, and 146, respectively; and (b) at least two cyclic PYY peptides, wherein the monoclonal antibody or antigen binding fragment thereof is conjugated to the at least two cyclic PYY peptides, wherein the at least two cyclic PYY peptides are represented by Formula I or a derivative or pharmaceutically acceptable salt thereof: wherein p is 0 or 1; m is 0, 1, 2, 3, 4, or 5; n is 1, 2, 3, or 4; q is 0 or 1; provided that q is 1 only when Z 30 is absent; BRIDGE is -Ph-CH 2 -S-, -triazolyl-, -NHC(O)CH 2 S-, -SCH 2 C(O)NH-, -(OCH 2 CH 2 ) 2 NHC(O)CH 2 S, -NHC(O)-, or -CH 2 S-; Z 4 is K, A, E, S, or R; Z 7 is A or K; Z 9 is G or K; Z 11 is D or K; Z 22 is A or K; Z 23 is S or K; Z 26 is A or H; Z 30 is L , W, absent, or K; provided that Z 30 is absent only when q is 1; Z 34 is Z 35 is wherein the derivative is the compound of Formula I that is modified by one or more processes selected from the group consisting of amidation, glycosylation, carbamylation, sulfation, phosphorylation, cyclization, lipidation, and pegylation. (a) a monoclonal antibody or an antigen binding fragment thereof, wherein the monoclonal antibody or antigen binding fragment thereof comprises a heavy chain complementarity determining region 1 (HCDR1), a HCDR2, a HCDR3, a light chain complementarity determining region 1 (LCDR1), a LCDR2, and a LCDR3, having the polypeptide sequences of SEQ ID NO: 141, 142, 143, 144, 145, and 146, respectively; and (b) at least two cyclic PYY peptides, wherein the monoclonal antibody or antigen binding fragment thereof is conjugated to the at least two cyclic PYY peptides, wherein the at least two cyclic PYY peptides are represented by Formula I or a derivative or pharmaceutically acceptable salt thereof: wherein p is 0 or 1; m is 0, 1, 2, 3, 4, or 5; n is 1, 2, 3, or 4; q is 0 or 1; provided that q is 1 only when Z 30 is absent; BRIDGE is -Ph-CH 2 -S-, -triazolyl-, -NHC(O)CH 2 S-, -SCH 2 C(O)NH-, -(OCH 2 CH 2 ) 2 NHC(O)CH 2 S, -NHC(O)-, or -CH 2 S-; Z 4 is K, A, E, S, or R; Z 7 is A or K; Z 9 is G or K; Z 11 is D or K; Z 22 is A or K; Z 23 is S or K; Z 26 is A or H; Z 30 is L , W, absent, or K; provided that Z 30 is absent only when q is 1; Z 34 is Z 35 is p is 0 or 1; m is 0, 1, 2, 3, 4, or 5; n is 1, 2, 3, or 4; q is 0 or 1; provided that q is 1 only when Z 30 is absent; BRIDGE is -Ph-CH 2 -S-, -triazolyl-, -NHC(O)CH 2 S-, -SCH 2 C(O)NH-, -(OCH 2 CH 2 ) 2 NHC(O)CH 2 S, -NHC(O)-, or -CH 2 S-; Z 4 is K, A, E, S, or R; Z 7 is A or K; Z 9 is G or K; Z 11 is D or K; Z 22 is A or K; Z 23 is S or K; Z 26 is A or H; Z 30 is L , W, absent, or K; provided that Z 30 is absent only when q is 1; Z 34 is Z 35 is wherein the derivative is the compound of Formula I that is modified by one or more processes selected from the group consisting of amidation, glycosylation, carbamylation, sulfation, phosphorylation, cyclization, lipidation, and pegylation. <EOS>